ly3090106
mAbexperimentalMulti-specific
Clinical trial activity
6 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Aug 1, 2013 (NCT01925157)
Timeline
Indications
Mechanism of action
TNFSF13B inhibitor
- Interleukin 17AINHIBITOR
IL17A inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3990000 ↗
Also known as
- ly3090106
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06993610 | Phase 2 | May 16, 2025 | Zura Bio Inc |
| NCT06843239 | Phase 2 | Feb 6, 2025 | Zura Bio Inc |
| NCT04563195 | Phase 2/Phase 3 (Phase 3) | Nov 30, 2020 | Stanford University |
| NCT03736772 | Phase 1 | Nov 19, 2018 | Eli Lilly |
| NCT02614716 | Phase 1 | Dec 1, 2015 | Eli Lilly |
| NCT01925157 | Phase 1 | Aug 1, 2013 | Eli Lilly |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 3 | 3 | 1 | 2013 |
| Zura Bio Inc | For profit | 2 | 2 | 1 | 2025 |
| Stanford University | Academic/Hospital | 1 | 1 | 1 | 2020 |
3 organizations
Page 1 / 1